Ad hoc and press releases

Here, we have compiled the press and ad hoc releases from the past years. All releases can be viewed directly on the screen or downloaded in PDF format.

2011
12/30/2011 Ad hoc update	Ad hoc release according to § 15 WpHG: STADA: Purchase of a branded product portfolio in Eastern Europe as well as in the Middle East successfully concluded – Central Europe still open More information
12/05/2011 Corporate News	STADA subsidiary increases commitment to charity More information
12/01/2011 Corporate News	STADA strengthens long-term refinancing with successful securing of promissory notes in the amount of EUR 400 million More information
11/23/2011 Corporate News	STADA sales companies very successful in large-volume 7th AOK tender in the German generics market More information
11/10/2011 Corporate News	STADA: Stabilization of business outlook in Serbia after letter of comfort from Serbian government More information
11/10/2011 Corporate News	STADA 1-9/2011: Good development of sales and operating earnings – High burden on reported key earnings figures through one-time special effects – Confirmation of long-term growth targets More information
11/09/2011 Ad hoc update	Ad hoc release according to § 15 WpHG: STADA signs contract on the purchase of a generics business in Switzerland More information
10/31/2011 Corporate News	STADA sales companies very successful in tenders for discount agreements with various German public health insurance organizations More information
09/21/2011 Ad hoc release	Ad hoc release according to § 15 WpHG: STADA: Increased risk of default on outstanding receivables from Serbian pharmaceutical wholesalers leads to burdening one-time special effects of approx. EUR 97 million before taxes More information
08/30/2011 Corporate News	STADA and Richter cooperate for development of two biosimilar products for two monoclonal antibodies: Rituximab and Trastuzumab More information
08/11/2011 Corporate News	STADA: Positive business development in H1/2011 – Increase of Group sales and all key earnings figures – Outlook remains positive for 2011/2012 More information
08/01/2011 Corporate News	STADA sales companies achieve very good results in fourth DAK tender in the German generics market More information
07/22/2011 Ad hoc update	Ad hoc release according to § 15 WpHG: STADA and Grünenthal sign contracts on the purchase of a branded product portfolio in Central and Eastern Europe as well as the Middle East More information
06/16/2011 Corporate News	STADA AGM 2011: Executive Board continues to expect further growth in Group sales and earnings in 2011 and 2012 More information
05/26/2011 Corporate News	STADA acquires British branded product Cetraben® for GBP 30 million (approx. EUR 34.6 million) More information
05/19/2011 Ad hoc release	Ad hoc release according to § 15 WpHG: STADA negotiating the purchase of a generics business in Switzerland More information
05/12/2011 Ad hoc release	Ad hoc release according to § 15 WpHG: STADA and Grünenthal in exclusive negotiations on the purchase of a branded product portfolio in Central and Eastern Europe as well as the Middle East for approx. EUR 360 million More information
05/12/2011 Corporate News	STADA: Positive business development in Q1/2011 – Increase of Group sales and all key earnings figures – Outlook remains positive for 2011/2012 More information
05/11/2011 Corporate News	STADA Group achieves strong result in 6th AOK tender in the German generics market More information
03/30/2011 Corporate News	STADA: Good operating results confirm successful financial year 2010 – positive outlook for 2011/2012 More information
02/28/2011 Ad hoc release	Ad hoc release according to § 15 WpHG: STADA: 2010 preliminary results confirm operationally successful year – dividend to amount to EUR 0.37 with unchanged distribution ratio – positive outlook for 2011/2012 More information